Skip to main content
OpenTrials

Clinical trial condition

Hemic and Lymphatic Diseases

Explore clinical trials studying Hemic and Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

21,073 public trials 3,988 recruiting studies
Refine in advanced search Browse all conditions

Hemic and Lymphatic Diseases trial results

Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

NCT03739814

Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, DNA Virus Infections, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 280 locations
View Trial Details
Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Hemic and Lymphatic Diseases, +10 more
Locations
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Highlands Oncology Group Fayetteville, Arkansas, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
View all 67 locations
View Trial Details
Recruiting

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

NCT06806033

Conditions
Cytokine Release Syndrome, Disease Attributes, Hemic and Lymphatic Diseases, +17 more
Locations
  • Alaska Oncology & Hematology, LLC Anchorage, Alaska, United States
  • Community Cancer Institute (CCI) Clovis, California, United States
  • Providence Medical Foundation Fullerton, California, United States
  • Los Angeles Cancer Network Glendale, California, United States
View all 53 locations
View Trial Details
Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Kaiser Permanente Southern California Irvine, California, United States
  • University of California San Diego (Ucsd) Moores Cancer Center La Jolla, California, United States
View all 214 locations
View Trial Details
Recruiting

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 49 locations
View Trial Details
Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069

Conditions
Hemic and Lymphatic Diseases, Histiocytosis, Histiocytosis, Langerhans-Cell, +6 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
View all 120 locations
View Trial Details
Recruiting

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, +8 more
Locations
  • City of Hope Duarte, California, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
View Trial Details

Related conditions